News | March 20, 2024
AstraZeneca buys biopharmaceutical company Fusion
To accelerate the development of next-generation radioconjugates to treat cancer
To accelerate the development of next-generation radioconjugates to treat cancer
Lonza plans to invest approximately CHF 500 million to upgrade the facility
The plan essentially was to separate Aster’s India and GCC businesses to unlock long-term value
A five-day inspection was concluded successfully with no critical and no major observations raised
Additional capacity broadens Grace’s fine chemical capabilities for API production
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India
Both organisations enter into a long- term collaboration to expand patient access in India
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Mungara has over 25+ years of experience in the supply chain domain
Subscribe To Our Newsletter & Stay Updated
